Stone House Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Stone House Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368	Buy	+3	New	+$313	﹤0.01%	1089

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Stone House Investment Management's PTGX Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 3 shares worth $368. The stake represents ﹤0.01% of the portfolio and ranks #1089 among its holdings.

343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Stone House Investment Management held 3 shares of Protagonist Therapeutics worth $368 as of Q2 2026.
Protagonist Therapeutics was a new Stone House Investment Management position in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1089 holding.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.